<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262067</url>
  </required_header>
  <id_info>
    <org_study_id>AVF3694g</org_study_id>
    <secondary_id>BO20094</secondary_id>
    <nct_id>NCT00262067</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)</brief_title>
  <official_title>A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate
      the efficacy and safety of bevacizumab in combination with chemotherapy compared with
      chemotherapy alone in subjects with previously untreated metastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes a blinded treatment phase, an optional open-label post-progression phase,
      and a survival follow-up phase. During the blinded treatment phase, patients receive
      chemotherapy and study drug (bevacizumab or placebo) every 3 weeks until disease progression,
      treatment-limiting toxicity, or death due to any cause. The optional open-label
      post-progression phase consists of chemotherapy treatment (per investigator discretion) and
      optional treatment with open-label bevacizumab. Patients who complete the study or who
      discontinue from treatment (regardless of participation in the optional open-label
      post-progression phase) will be followed for survival and subsequent anti-cancer therapies
      every 4 months until death, withdrawal of consent, loss to follow-up, or study termination.
      Patients who discontinue from treatment during the blinded treatment phase for reasons other
      than disease progression will have tumor assessments every 9 weeks until documented disease
      progression or death.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2005</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)</time_frame>
    <description>PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)</time_frame>
    <description>An objective response was defined as a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart as determined by the investigator using RECIST. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)</time_frame>
    <description>Duration of objective response was defined as the time from the first tumor assessment that led to a determination of an objective response to the time of disease progression or death due to any cause, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)</time_frame>
    <description>Overall survival was defined as the time from randomization until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Survival</measure>
    <time_frame>Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)</time_frame>
    <description>1-year survival was defined as the percentage of patients who were alive 1 year after randomization.
The percentage of patients alive at 1 year was determined using Kaplan-Meier analyses and the 95% confidence intervals were computed using the Brookmeyer-Crowley method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) as Determined by the Independent Review Committee Using Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)</time_frame>
    <description>PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the Independent Review Committee using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1237</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.</description>
    <arm_group_label>Bevacizumab + chemotherapy</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo consisted of the vehicle for bevacizumab without the antibody.</description>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.
Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle
Docetaxel 75-100 mg/m^2 IV
Paclitaxel protein-bound particles (Abraxane®) 260 mg/m^2 IV
Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle
5-fluorouracil 500 mg/m^2 IV + epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV
5-fluorouracil 500 mg/m^2 IV + doxorubicin 50 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV
Doxorubicin 50-60 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV
Epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV
Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle</description>
    <arm_group_label>Bevacizumab + chemotherapy</arm_group_label>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the breast, with
             measurable or non-measurable locally recurrent or metastatic disease.

          -  Signed Informed Consent Form.

          -  Age ≥ 18 years.

          -  For women of childbearing potential, use of accepted and effective method of
             non-hormonal contraception.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Ability and capacity to comply with study and follow-up procedures.

          -  For anthracycline cohort only: Adequate left ventricular function at study entry,
             defined as a left ventricular ejection fraction (LVEF) ≥ 50% by either multigated
             acquisition (MUGA) scan scan or echocardiography (ECHO).

          -  For subjects who have received recent radiation therapy, recovery prior to baseline
             (Day 0) from any significant (Grade ≥ 3) acute toxicity.

        Exclusion Criteria:

          -  Unknown human epidermal growth factor receptor 2 (HER2) status or known HER2-positive
             status.

          -  Prior chemotherapy for locally recurrent or metastatic disease.

          -  Prior hormonal therapy less than 1 week prior to Day 0.

          -  Prior adjuvant or neoadjuvant chemotherapy within 12 months prior to Day 0.

          -  For anthracycline cohort only: Prior anthracycline as part of neoadjuvant or adjuvant
             therapy for localized breast cancer.

          -  Investigational therapy within 28 days of Day 0.

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0, or anticipation of need for major surgical procedure during the course
             of the study.

          -  Minor surgical procedures, such as fine needle aspirations or core biopsies, within 7
             days prior to Day 0.

          -  Prior therapy with bevacizumab, sorafenib, sunitinib, or other vascular endothelial
             growth factor (VEGF) pathway-targeted therapy.

          -  Known brain or other central nervous system (CNS) metastases.

          -  Blood pressure of &gt; 150/100 mmHg.

          -  Unstable angina.

          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF).

          -  History of myocardial infarction within 6 months prior to Day 0.

          -  History of stroke or transient ischemic attack within 6 months prior to Day 0.

          -  Clinically significant peripheral vascular disease.

          -  Evidence of bleeding diathesis or coagulopathy.

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 0.

          -  Serious non-healing wound, ulcer, or bone fracture.

          -  Pregnancy (positive serum pregnancy test) or lactation.

          -  Inadequate organ function, as evidenced by any of the following laboratory values:
             Absolute neutrophil count &lt; 1500/uL; platelet count &lt; 100,000/uL; total bilirubin &gt;
             1.5 mg/dL; alkaline phosphatase, AST, and/or ALT &gt; 2x upper limit of normal (ULN) (&gt;
             5x ULN in subjects with known liver or, for alkaline phosphatase elevations, bone
             involvement); alkaline phosphatase &gt; 2x ULN (&gt; 7x ULN in subjects with known bone
             involvement); serum creatinine &gt; 2.0 mg/dL; partial thromboplastin time (PTT) and/or
             either international normalized ratio (INR) or prothrombin time (PT) &gt; 1.5x upper
             limit of normal (except for subjects receiving anti-coagulation therapy); urine
             protein/creatinine ratio &gt; 1.0 at screening for U.S. subjects, or urine dipstick for
             proteinuria &gt;/= 1+ at screening followed by 24-hour urine collection demonstrating &gt; 1
             g protein/24 hr for ex-U.S. subjects.

          -  Uncontrolled serious medical or psychiatric illness.

          -  Active infection requiring intravenous (iv) antibiotics at Day 0.

          -  History of other malignancies within 5 years of Day 0 except for tumors with a
             negligible risk for metastasis or death, such as adequately controlled basal cell
             carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix
             (subjects with a history of bilateral breast cancer will be eligible).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo Faoro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Geelong</city>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malvern</city>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southport</city>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wahroonga</city>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waratah</city>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wollongong</city>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22260-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <zip>40170-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Andre</city>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hania</city>
        <zip>73300</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyunggi-do</city>
        <zip>411-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Acapulco</city>
        <zip>39670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merida</city>
        <zip>97500</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <zip>64380</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amstelveen</city>
        <zip>1186 AH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delft</city>
        <zip>2600 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Callao</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quezon City</city>
        <zip>1114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelyabinsk</city>
        <zip>454 087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivanovo</city>
        <zip>153040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <zip>420111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117837</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <zip>390011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <zip>443066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>UFA</city>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elche</city>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Laguna</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gaevle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherkassy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lvov</city>
        <zip>79031</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <zip>65055</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporozhye</city>
        <zip>69104</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelsmford</city>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Epping</city>
        <zip>CM16 6TN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huddersfield</city>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Swansea</city>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montevideo</city>
        <zip>11200</zip>
        <country>Uruguay</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Uruguay</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2005</study_first_submitted>
  <study_first_submitted_qc>December 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <results_first_submitted>August 20, 2013</results_first_submitted>
  <results_first_submitted_qc>August 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 25, 2013</results_first_posted>
  <disposition_first_submitted>September 1, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 1, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 2, 2009</disposition_first_posted>
  <last_update_submitted>November 18, 2013</last_update_submitted>
  <last_update_submitted_qc>November 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen</title>
          <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
        </group>
        <group group_id="P2">
          <title>Placebo to Bevacizumab + Taxane or Anthracycline-based Regimen</title>
          <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
        </group>
        <group group_id="P3">
          <title>Bevacizumab 15 mg/kg + Capecitabine</title>
          <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
        </group>
        <group group_id="P4">
          <title>Placebo to Bevacizumab + Capecitabine</title>
          <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="415"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="409"/>
                <participants group_id="P4" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="196"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="193"/>
                <participants group_id="P4" count="93"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="216"/>
                <participants group_id="P4" count="113"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="186"/>
                <participants group_id="P4" count="99"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's Decision to Terminate Study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Withdrew for Survival Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen</title>
          <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
        </group>
        <group group_id="B2">
          <title>Placebo to Bevacizumab + Taxane or Anthracycline-based Regimen</title>
          <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
        </group>
        <group group_id="B3">
          <title>Bevacizumab 15 mg/kg + Capecitabine</title>
          <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
        </group>
        <group group_id="B4">
          <title>Placebo to Bevacizumab + Capecitabine</title>
          <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="415"/>
            <count group_id="B2" value="207"/>
            <count group_id="B3" value="409"/>
            <count group_id="B4" value="206"/>
            <count group_id="B5" value="1237"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="289"/>
                    <measurement group_id="B4" value="137"/>
                    <measurement group_id="B5" value="881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="413"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="408"/>
                    <measurement group_id="B4" value="204"/>
                    <measurement group_id="B5" value="1232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.</description>
        <time_frame>Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Bevacizumab + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O3">
            <title>Bevacizumab 15 mg/kg + Capecitabine</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Bevacizumab + Capecitabine</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)</title>
          <description>PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="8.6" upper_limit="10.1"/>
                    <measurement group_id="O2" value="8.0" lower_limit="6.7" upper_limit="8.4"/>
                    <measurement group_id="O3" value="8.6" lower_limit="8.1" upper_limit="9.5"/>
                    <measurement group_id="O4" value="5.7" lower_limit="4.3" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>An objective response was defined as a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart as determined by the investigator using RECIST. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.</description>
        <time_frame>Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment. Only patients with measurable disease at baseline were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Bevacizumab + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O3">
            <title>Bevacizumab 15 mg/kg + Capecitabine</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Bevacizumab + Capecitabine</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)</title>
          <description>An objective response was defined as a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart as determined by the investigator using RECIST. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment. Only patients with measurable disease at baseline were included in the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="345"/>
                <count group_id="O2" value="177"/>
                <count group_id="O3" value="325"/>
                <count group_id="O4" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" lower_limit="45.9" upper_limit="56.7"/>
                    <measurement group_id="O2" value="37.9" lower_limit="30.7" upper_limit="45.2"/>
                    <measurement group_id="O3" value="35.4" lower_limit="30.2" upper_limit="40.6"/>
                    <measurement group_id="O4" value="23.6" lower_limit="17.6" upper_limit="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>Duration of objective response was defined as the time from the first tumor assessment that led to a determination of an objective response to the time of disease progression or death due to any cause, whichever occurred first.</description>
        <time_frame>Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment. Only patients with measurable disease at baseline and who had an objective response were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Bevacizumab + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O3">
            <title>Bevacizumab 15 mg/kg + Capecitabine</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Bevacizumab + Capecitabine</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)</title>
          <description>Duration of objective response was defined as the time from the first tumor assessment that led to a determination of an objective response to the time of disease progression or death due to any cause, whichever occurred first.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment. Only patients with measurable disease at baseline and who had an objective response were included in the analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="7.2" upper_limit="10.7"/>
                    <measurement group_id="O2" value="7.1" lower_limit="6.2" upper_limit="8.8"/>
                    <measurement group_id="O3" value="9.2" lower_limit="8.5" upper_limit="10.4"/>
                    <measurement group_id="O4" value="7.2" lower_limit="5.1" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival was defined as the time from randomization until death from any cause.</description>
        <time_frame>Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Bevacizumab + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O3">
            <title>Bevacizumab 15 mg/kg + Capecitabine</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Bevacizumab + Capecitabine</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival was defined as the time from randomization until death from any cause.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="25.6" upper_limit="31.4"/>
                    <measurement group_id="O2" value="NA" lower_limit="23.6">The median and the upper limit of the confidence interval could not be estimated due to too few events.</measurement>
                    <measurement group_id="O3" value="25.7" lower_limit="22.0" upper_limit="28.4"/>
                    <measurement group_id="O4" value="22.8" lower_limit="20.5" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1-year Survival</title>
        <description>1-year survival was defined as the percentage of patients who were alive 1 year after randomization.
The percentage of patients alive at 1 year was determined using Kaplan-Meier analyses and the 95% confidence intervals were computed using the Brookmeyer-Crowley method.</description>
        <time_frame>Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Bevacizumab + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O3">
            <title>Bevacizumab 15 mg/kg + Capecitabine</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Bevacizumab + Capecitabine</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>1-year Survival</title>
          <description>1-year survival was defined as the percentage of patients who were alive 1 year after randomization.
The percentage of patients alive at 1 year was determined using Kaplan-Meier analyses and the 95% confidence intervals were computed using the Brookmeyer-Crowley method.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7" lower_limit="76.8" upper_limit="84.5"/>
                    <measurement group_id="O2" value="83.2" lower_limit="78.1" upper_limit="88.4"/>
                    <measurement group_id="O3" value="81.0" lower_limit="77.1" upper_limit="84.8"/>
                    <measurement group_id="O4" value="74.8" lower_limit="68.7" upper_limit="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) as Determined by the Independent Review Committee Using Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <description>PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the Independent Review Committee using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.</description>
        <time_frame>Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)</time_frame>
        <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O2">
            <title>Placebo to Bevacizumab + Taxane or Anthracycline-based Regimen</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O3">
            <title>Bevacizumab 15 mg/kg + Capecitabine</title>
            <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Bevacizumab + Capecitabine</title>
            <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) as Determined by the Independent Review Committee Using Response Evaluation Criteria in Solid Tumors (RECIST)</title>
          <description>PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the Independent Review Committee using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.</description>
          <population>Intent-to-treat population: All randomized patients, regardless of whether they received any study drug or completed the full course of treatment.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="409"/>
                <count group_id="O4" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="9.9" upper_limit="12.1"/>
                    <measurement group_id="O2" value="8.3" lower_limit="8.0" upper_limit="9.9"/>
                    <measurement group_id="O3" value="9.8" lower_limit="8.4" upper_limit="10.4"/>
                    <measurement group_id="O4" value="6.2" lower_limit="4.7" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from the first treatment until 30 days after the last treatment during the blinded treatment phase or the start date of the optional open-label treatment phase, whichever occurred first (up to 3 years 2 months).</time_frame>
      <desc>Safety population: All randomized patients who received any study treatment, defined as at least 1 full or partial dose of either study drug or chemotherapy. There were a total of 1220 patients in the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab 15 mg/kg + Taxane or Anthracycline-based Regimen</title>
          <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
        </group>
        <group group_id="E2">
          <title>Placebo to Bevacizumab + Taxane or Anthracycline-based Regimen</title>
          <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + either a taxane or anthracycline-based standard chemotherapy for metastatic breast cancer.</description>
        </group>
        <group group_id="E3">
          <title>Bevacizumab 15 mg/kg + Capecitabine</title>
          <description>Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
        </group>
        <group group_id="E4">
          <title>Placebo to Bevacizumab + Capecitabine</title>
          <description>Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + capecitabine standard chemotherapy for metastatic breast cancer.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="72" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Febrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia of malignancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Ileal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Jejunitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hepatorenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Herpes oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Salpingo−oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Sweat gland infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Radiation oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassiumiIncreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Rotavirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Spinal deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Tumour ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Coma hepatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Reversible posterior leukoencephalopathy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Tracheomalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Palmar−plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="413"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="404"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="201"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Genentech, Inc.</organization>
      <phone>800 821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

